NEUROLOGY.
AMYOTROPHIC LATERAL SCLEROSIS.
DE-RISK EFFICACY & SAFETY BEFORE THE CLINIC.
Benefits.
By providing human-relevant functional data on patient-derived motor neurons, NETRI ALS platform enhances clinical risk assessment. It allows early detection of compound efficacy, enabling better prediction of therapeutic benefit and safety, guiding dose selection, and reducing the risk of late-stage clinical failures.
Description.
Create compartmentalized monoculture with healthy / C9orf72 or patient derived motor neurons to assess compound efficacy to regain motor neuron function.
Readouts.
• Electrophysiological recordings of motor neurons.
• Mediators release dosage (ELISA).
• Imaging.
Advantages.
• Direct recording enabling the discrimination of healthy vs ALS functional phenotype.
• Ability to detect compound concentration dependent effect on neuronal cell functionality.
• Access to ALS-patient-derived cells.
NEUROTOXICITY SAFETY.
DE-RISK ADVERSE EFFECTS BEFORE THE CLINIC.
Benefits.
By providing human-relevant, longitudinal neurotoxicity data early in drug development, NETRI Neurotoxicity platform improves clinical risk assessment. It enables detection of subtle neuronal dysfunctions that traditional models may miss, helping to predict adverse effects and refine dosing, formulation, or candidate selection, ultimately reducing late-stage failures and enhancing patient safety.
Description.
Innervate with glutamatergic neurons and record the response to compound of a Brain Organoid suspended in BioMimesys® brain hydroscaffol. Glutamatergic neurons provide a constant sensing recording baseline over time.
Readouts.
• MEA recordings.
• Digital Signatures.
• Imaging.
Advantages.
• Consistent innervation, potentially deeper that surface, providing better MEA signal than electrodes.
• Can be performed non-destructively over time.
• Brain organoids can be consistently matured in NETRI’s DuaLink Well MEA devices.
DRUG INDUCED SEIZURE.
DE-RISK SEIZURE EFFECTS BEFORE THE CLINIC.
Benefits.
By enabling early, human-relevant detection of pro-convulsant liability, NETRI Drug-Induced Seizure platform improves clinical risk assessment. Real-time electrophysiological readouts of excitatory/inhibitory network balance allow prediction of seizure risk and dose-dependent effects, supporting safer candidate selection and reducing late-stage clinical failures.
Description.
Compartmentalized human iPSC-derived glutamatergic + GABAergic neurons co-cultured with astrocytes to model excitatory/inhibitory imbalance underlying seizures. Built on NETRI’s Neuron-as-a-Sensor (NaaS) technology to generate digital electrophysiological signatures predicting seizure liability.
Readouts.
• MEA electrophysiology (WMFR, bursts, synchrony, network activity).
• Dose-response profiling.
• Digital signature generation & ML-based clustering.
• Imaging for cell composition & QC validation.
Advantages.
• Human-relevant multi-cellular model.
• Real-time functional readout of network excitability.
• Early prediction of pro-convulsant risk.
• Scalable NAM approach.
NEUROLOGY.
POTENTIAL APPLICATIONS.
• Alzheimer’s Disease: co-culture of hiPSC-derived glutamatergic neurons with patient CSF.
• Parkinson’s Disease: co-culture of hiPSC-derived glutamatergic and dopaminergic neurons with misfolded protein oligomers in glutamatergic neurons compartment.
• Huntington’s Disease: co-culture of hiPSC-derived GABAergic neurons and medium spiny striatal neurons with Pridopidine in each compartments.
• BBB Penetration: tri-culture of hiPSC-derived glutamatergic neurons and pericytes / astrocytes and endothelial cells to create an innervated and vascularized BBB platform.
• Sensory Innervated NMJ: tri-culture of hiPSC-derived sensory neurons and primary muscle cells and hiPSC-derived motor neurons with compound in muscle and motor neurons compartments.
OUR OFFERS.
Initialization.
Creation of NaaS biology platform and NaaS Model for a target application.
• In Your Lab: Develop your NaaS Model on your own terms.
• At NETRI: Let NETRI Develop your NaaS Model.
Upscaling.
Build up of Digital NaaS model through Training Library of 100s of reference compounds.
• Pre-Licensing: Test your molecules using your NaaS Model.
Screening & Drug Design.
Transfer of methodology, devices and predictive model capabilities to client.
• Licensing: Screen your molecules using an existing NaaS Model.
Regulatory Approval.
Extension of approved NaaS Model to multiple clients. Larger deals with CROs to handle volumes.
• Licensing & milestones.
